AltheaDx, Inc., a San Diego, CA-based personalized medicine company, raised $30m in Series C financing.
The round was led by WuXi Healthcare Ventures with participation from new investors WuXi PharmaTech, Ally Bridge Group and ALMA Life Sciences.
The company intends to use the funds to invest in prospective outcome trials for its IDgenetix® testing portfolio, product enhancements, international opportunities and expansion of commercial capabilities.
Led by Greg Hamilton, CEO, AltheaDx is a commercial stage personalized medicine company advancing the IDgenetix® pharmacogenetics (PGx) testing portfolio which enables personalized therapeutic decisions for patients suffering from some of the most prevalent clinical conditions, including: cardiovascular disease, neuropsychiatric disorders and pain.
The company operates a CAP-accredited, CLIA-certified laboratory in San Diego.